Tag

Johnson And Johnson

All articles tagged with #johnson and johnson

business1 day ago•2 min saved

J&J makes a $1B bet on degrader antibody conjugates with Firefly Bio

Johnson & Johnson is paying $1 billion upfront to acquire Firefly Bio and its Firelink degrader antibody conjugate (DAC) platform, gaining a technology that links catalytic protein degraders to antibodies to target KRAS-driven tumors and expand its innovative medicine pipeline. Firefly has shown preclinical tumor reductions at very low doses, and the deal underscores rising pharma interest in DACs, which are drawing attention after multiple partnerships and acquisitions in the space.

via Fierce Biotech|

#business #degrader-antibody-conjugates #firefly-bio

science9 days ago•34 min saved

Cancer drug erases tumors in chemo-resistant cancers, early trial results show

In a multi-country trial, Johnson & Johnson’s amivantamab shrank or eradicated tumors in patients with head and neck cancer (and some lung cancers) that had stopped responding to chemotherapy or immunotherapy; 43 of 102 patients responded (28 partial shrinkages, 15 complete disappearances), with results to be presented at ASCO in Chicago; the drug works by targeting tumor growth proteins and activating the immune system, and median survival was about 12.5 months, with ongoing trials to explore broader use.

via Yahoo News Canada|

#amivantamab #cancer #head-and-neck-cancer

health2 months ago•9 min saved

Lancet retracts 1977 unsigned talc commentary after uncovering Johnson & Johnson ties

The Lancet has retracted a 1977 unsigned commentary on cosmetic talc after discovering the author was a paid Johnson & Johnson consultant, revealing an undeclared conflict of interest; editors say such unsigned pieces would not be published today, and the decision comes amid decades of talc-related litigation and ongoing debates over asbestos testing in cosmetics, including a FDA rule proposal later withdrawn in 2025.

via Retraction Watch|

#conflicts-of-interest #health #johnson-and-johnson

healthcare2 months ago•2 min saved

J&J’s new psoriasis pill could reshape the treatment landscape

Johnson & Johnson won U.S. approval for Icotyde, a daily oral medication for moderate-to-severe plaque psoriasis in patients 12 and older, designed to mimic the effects of top-selling injectables like Skyrizi and Tremfya without injections. The pill could expand the patient market and is projected to reach more than $5 billion in peak annual sales, potentially reshaping competition in a multibillion-dollar field.

via statnews.com|

#fda-approval #healthcare #icotyde

business3 months ago•4 min saved

J&J Bets Big on U.S. Cell-Therapy Manufacturing with $1B Pennsylvania Facility

Johnson & Johnson announced more than a $1 billion investment to build a next-generation cell-therapy manufacturing facility in Lower Gwynedd, Montgomery County, Pennsylvania, expanding U.S. manufacturing capacity, creating 500+ biomanufacturing jobs and up to 4,000 construction roles, as part of a broader $55 billion U.S. investment through 2029 to advance cancer, immune-mediated, and neurological therapies.

via Johnson & Johnson|

#biomanufacturing #business #cell-therapy

business-news3 months ago•53 min saved

Johnson & Johnson to invest over $1B in a new cell-therapy facility in Lower Gwynedd

Johnson & Johnson announced a more-than-$1 billion plan to build a next-generation cell-therapy manufacturing facility on a 154-acre site in Spring House, Lower Gwynedd, to expand U.S. manufacturing for cancer, immune-mediated and neurological diseases. The project is expected to create about 4,000 construction jobs and 500 skilled biomanufacturing roles; J&J already operates a large facility in the area with about 2,500 workers. Pennsylvania officials welcomed the investment as a boost to the state's life sciences and workforce.

via Around Ambler|

#business-news #investment #johnson-and-johnson

business5 months ago•2 min saved

Johnson & Johnson to Build Second Facility in Wilson, Creating Hundreds of Jobs

Johnson & Johnson is expanding its operations in Wilson, North Carolina, with a multibillion-dollar investment to build a new factory that will produce cancer drugs, creating hundreds of new jobs. The state is supporting this growth with a $12 million program to train workers, highlighting North Carolina's appeal for life sciences companies and its focus on workforce development.

via WRAL|

#business #economic-development #johnson-and-johnson

business5 months ago•1 min saved

J&J and Trump Administration Agree on Drug Price Reductions and Tariff Relief

Johnson & Johnson has reached an agreement with the US government to lower drug prices for Americans in exchange for tariff exemptions, participating in initiatives to make medicines more affordable and building new manufacturing facilities in the US as part of a broader investment plan.

via Reuters|

#business #drug-prices #johnson-and-johnson

business5 months ago•1 min saved

J&J and U.S. Government Agree on Drug Price Cuts and Tariff Exemptions

Johnson & Johnson has reached an agreement with the U.S. government to lower drug prices for Americans in exchange for tariff exemptions, participating in discounted drug sales and expanding manufacturing investments in the U.S.

via CNBC|

#business #drug-prices #johnson-and-johnson

business5 months ago•4 min saved

Johnson & Johnson Agrees to Lower Drug Prices in New U.S. Deal

Johnson & Johnson has reached a voluntary agreement with the U.S. government to improve access to medicines and lower costs for Americans, including discounts and tariff exemptions, while also investing $55 billion in U.S. manufacturing and research, with new facilities announced in North Carolina and Pennsylvania.

via Johnson & Johnson|

#business #cost-reduction #johnson-and-johnson

business5 months ago•4 min saved

Johnson & Johnson Acquires Halda Therapeutics to Advance Cancer Treatments

Johnson & Johnson has completed its $3.05 billion acquisition of Halda Therapeutics, a biotech company with a novel RIPTAC platform for developing targeted oral therapies for solid tumors, including prostate cancer, aiming to revolutionize cancer treatment and expand its oncology portfolio.

via Johnson & Johnson|

#business #cancer-treatment #halda-therapeutics

business5 months ago•0 min saved

J&J cancels eczema drug post-$1.25B acquisition

Johnson & Johnson has discontinued its experimental eczema medication after it failed to meet efficacy standards, ending its $1.25 billion investment in the drug.

via Endpoints News|

#acquisition #business #drug-development

health5 months ago•1 min saved

Johnson & Johnson Stops Mid-Stage Eczema Drug Trial

Johnson & Johnson has discontinued its mid-stage trial of the experimental eczema drug JNJ-5939 after it failed to meet efficacy goals, but remains committed to developing other treatments for atopic dermatitis.

via CNBC|

#atopic-dermatitis #clinical-trial #drug-development

business5 months ago•2 min saved

Johnson & Johnson Announces Results from Phase 2b DUPLEX-AD Study

Johnson & Johnson announced that their Phase 2b DUPLEX-AD study for JNJ-5939 in treating moderate to severe atopic dermatitis was terminated early after not meeting efficacy criteria, though the drug was well tolerated. The company remains committed to developing new treatments for the high-need condition.

via Johnson & Johnson|

#atopic-dermatitis #business #clinical-trial

business5 months ago•3 min saved

J&J to Appeal $1.5 Billion Talc Cancer Verdict

A Baltimore jury awarded over $1.5 billion to Cherie Craft, who claimed J&J's talc products caused her asbestos-related cancer, and J&J plans to appeal, citing the verdict as egregious and unconstitutional. The case adds to thousands of lawsuits against J&J over talc-related health claims, which the company denies, asserting its products are safe.

via Reuters|

#business #johnson-and-johnson #legal-verdict